Protara Therapeutics, Inc. (TARA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Protara Therapeutics, Inc. (TARA) is down 20.8% since the beginning of the year. At $4 per share, TARA is trading 46.0% below its 52-week high of $8. Investors who bought $1,000 worth of TARA shares 5 years ago would now be looking at an investment worth $414.

Protara Therapeutics, Inc. (TARA) has returned -20.83% so far this year and 28.66% over the past 12 months. Over the last ten years, TARA has returned -33.11% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Oct 22, 2014, TARA's average daily return is +0.03%, while the average monthly return is +0.55%. At this rate, an investment would double in approximately 10.5 years.

Historically, 46% of months were positive and 54% were negative. The best month was May 2020 with a return of +122.0%, while the worst month was Mar 2019 at -82.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, TARA closed higher 44% of trading days. The best single day was Dec 5, 2024 with a return of +70.1%, while the worst single day was Mar 28, 2019 at -85.6%.

Protara Therapeutics, Inc. has an annualized alpha of -3.72%, beta of 0.84, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since October 23, 2014.

• This stock participated in 165.18% of S&P 500 Index downside but only -25.12% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TARA ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Protara Therapeutics, Inc. (TARA) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Protara Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Protara Therapeutics, Inc. was 99.86%, occurring on Nov 22, 2023. The portfolio has not yet recovered.

The current Protara Therapeutics, Inc. drawdown is 99.47%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Protara Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Protara Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.